Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 5/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.41 |
| ▸ | OPRL1 | P41146 | 2/20 | 0.41 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.39 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.39 |
| ▸ | CTSL | P07711 | 1/20 | 0.38 |
| ▸ | CTSB | P07858 | 1/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.38 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | DPP4 | P27487 | 1/20 | 0.38 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28699610 | 0.95 | TSHR (0.43) | TSHREPHX2OPRM1OPRL1FFAR1 | |
| SCHEMBL22509316 | 0.83 | TSHR (0.40) | TSHREPHX2OPRM1OPRL1FFAR1 | |
| SCHEMBL22509306 | 0.83 | TSHR (0.40) | TSHREPHX2OPRM1OPRL1FFAR1 | |
| SCHEMBL871442 | 0.82 | ADAM17 (0.46) | TSHREPHX2OPRM1OPRL1ALDH1A1 | |
| SCHEMBL2640274 | 0.81 | EPHX2 (0.47) | EPHX2OPRM1OPRL1AGTR2CTSL | |
| SCHEMBL32676611 | 0.79 | EPHX2 (0.44) | EPHX2OPRM1OPRL1CTSLCTSB | |
| SCHEMBL29157159 | 0.78 | SLC6A2 (0.40) | TSHRFFAR1GRIN2B | |
| SCHEMBL16486136 | 0.78 | ALDH1A1 (0.53) | TSHRCTSLCTSBCTSKALDH1A1 | |
| SCHEMBL7936878 | 0.78 | DPP4 (0.46) | EPHX2OPRM1OPRL1CTSLCTSB | |
| SCHEMBL5236350 | 0.77 | PPARG (0.43) | TSHREPHX2OPRM1OPRL1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12421251-B2 | Cystic fibrosis transmembrane conductance regulator modulating agents | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2025-09-23 | — | — | US | disclosed |
| CN-113905785-B | Cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2024-07-19 | — | — | CN | disclosed |
| EP-4335498-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | Vertex Pharmaceuticals Incorporated (US) | 2024-03-13 | — | — | EP | disclosed |
| EP-3946595-B1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | VERTEX PHARMA (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-3946595-B1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | VERTEX PHARMA (US) | 2023-11-15 | — | — | EP | disclosed |
| US-20220372047-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | VERTEX PHARMACEUTICALS INCORPORATED | 2022-11-24 | — | — | US | disclosed |
| EP-3946595-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | Vertex Pharmaceuticals Incorporated (US) | 2022-02-09 | — | — | EP | disclosed |
| CN-113905785-A | Cystic fibrosis transmembrane conductance regulator modulators | 弗特克斯药品有限公司 | 2022-01-07 | — | — | CN | disclosed |
| WO-2020206080-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-08 | — | — | WO | disclosed |
| WO-2020206080-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2020-10-08 | — | — | WO | disclosed |
| US-9670211-B2 | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection | HOFFMANN-LA ROCHE INC. (US) | 2017-06-06 | — | — | US | disclosed |
| EP-3033341-B1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN LA ROCHE (CH) | 2017-05-03 | — | — | EP | disclosed |
| US-20160229853-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | HOFFMANN-LA ROCHE INC. (US) | 2016-08-11 | — | — | US | disclosed |
| EP-3033341-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F.HOFFMANN-LA ROCHE AG (CH) | 2016-06-22 | — | — | EP | disclosed |
| WO-2015022263-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | F. HOFFMANN-LA ROCHE AG (CH) | 2015-02-19 | — | — | WO | disclosed |
| US-7566781-B2 | Imidazopyridine compound | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2009-07-28 | — | — | US | disclosed |
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | BANYU PHARMACEUTICAL., LTD. (JP) | 2007-10-25 | — | — | US | disclosed |
| EP-1748048-A1 | IMIDAZOPYRIDINE COMPOUND | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-01-31 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249659-A1 | melanin concentrating hormone receptor antagonist; preventing or treating vascular system diseases, nervous system disorders, metabolic disorders, urogenital diseases, respiratory diseases disorders; N-(2-ethyl-3-methylimidazo[1,2-a]pyridin-6-yl)-3-fluoro-4-(pyridin-2-ylmethoxy)benzamide | MC1R, MCHR2, MCHR1 | TSHR 24/4885EPHX2 2044/4885OPRM1 34/4885 |
| US-20220372047-A1 | CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR MODULATING AGENTS | CFTR, SCNN1G, CLCN2 | TSHR 947/4885EPHX2 2925/4885OPRM1 993/4885 |
| US-20160229853-A1 | NOVEL AZA-OXO-INDOLES FOR THE TREATMENT AND PROPHYLAXIS OF RESPIRATORY SYNCYTIAL VIRUS INFECTION | ZC3HAV1, TET1, IDO1 | TSHR 1321/4885EPHX2 3502/4885OPRM1 2456/4885 |
| US-12421251-B2 | Cystic fibrosis transmembrane conductance regulator modulating agents | CFTR, SCNN1G, CLCN2 | TSHR 947/4885EPHX2 2925/4885OPRM1 993/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.